Sandoz gains exclusive right to distribute Symjepi in USA

2 July 2018

Sandoz, a unit of Swiss pharma giant Novartis (NOVN: VX) has entered into an exclusive agreement with Adamis Pharmaceuticals (Nasdaq: ADMP) whereby Sandoz will distribute and commercialize Symjepi (epinephrine) 0.3mg Injection in the USA.

The agreement also covers Symjepi 15mg Injection, which is pending review by the US Food and Drug Administration. Financial terms of the arrangement have not been disclosed.

Symjepi was approved by the FDA last month and is a competitor to Mylan’s (Nasdaq: MYL)EpiPen (epinephrine) device that has recently been in short supply due to production hold ups at Pfizer (NYSE: PFE), which manufacturers the drug for Mylan, and has also been the subject of strong competition for price gouging. .

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK